FDA approves pembrolizumab with chemotherapy for advanced/recurrent endometrial carcinoma

Iván R. González, Medical Oncologist at Angeles Puebla Hospital, shared on X/Twitter:

“FDA approves pembrolizumab with chemotherapy for advanced/recurrent endometrial carcinoma. Thanks to the effectiveness of the KEYNOTE-868 study where the following was obtained:

dMMR cohort: SLP not reached vs. 6.5 months (HR 0.30; p<0.0001)
pMMR Cohort: SLP 11.1 months vs. 8.5 months (HR 0.60; p<0.0001)
Pembrolizumab, combined with chemotherapy, significantly improves progression-free survival in both groups.”

Source: Iván R. González/X